Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Economics Weekly: Another Possible Government Shutdown, Rising ACA Premiums, and Fiscal Cliffs Entering 2026

    In this Economics Weekly, Richard de Chazal responds to questions about another government shutdown and the enhanced Affordable Care Act (ACA) extended tax credits.

    Read more

  • Sirion Has Agreed to Receive a Majority Investment from Haveli Investments

    William Blair acted as exclusive financial advisor to Sirion, a portfolio company of Brookfield, Partners Group, Peak XV, and Tiger Global, in connection with its pending majority investment from Haveli Investments.

    Read more

  • Sur-Seal, LLC Has Been Acquired by Brodie Generational Capital Partners

    William Blair acted as the exclusive financial advisor to Sur-Seal, LLC, a portfolio company of Heartwood Partners, in connection with its sale to Brodie Generational Capital Partners.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures